Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.


Journal Article

The profile of action in animals of CQP 201-403, a novel 8 alpha-amino-ergoline, is in most aspects that of a very potent dopaminomimetic, both as a prolactin secretion inhibitor, and at the levels of the CNS and the cardiovascular system. Qualitatively CQP 201-403 differs slightly from bromocriptine and apomorphine in its effects on the CNS (no influence on serotonin metabolism in the rat cortex; induction of masculine mounting behavior in rats) and the cardiovascular system of the dog (reflex tachycardia in response to a blood-pressure fall). In man the new compound proved to be highly active in lowering prolactin serum levels and be more potent than bromocriptine (Parlodel).

Full Text

Cited Authors

  • Flückiger, E; Briner, U; Clark, B; Closse, A; Enz, A; Gull, P; Hofmann, A; Markstein, R; Tolcsvai, L; Wagner, HR

Published Date

  • May 1988

Published In

Volume / Issue

  • 44 / 5

Start / End Page

  • 431 - 436

PubMed ID

  • 3371446

Pubmed Central ID

  • 3371446

International Standard Serial Number (ISSN)

  • 0014-4754

Digital Object Identifier (DOI)

  • 10.1007/bf01940539


  • eng